aducanumab

aducanumab, Alzheimer’s, Analyst Color, Analyst Ratings, Benzinga, BIIB, Biotech, ESALY, fda, Marc Goodman, Movers, News, SVB Leerink, Top stories, Trading Ideas, US09062X1037

Biogen Soars As FDA Accepts Alzheimer’s Drug For Review In ‘Next Stage Of Aducanumab Saga’

Biogen Inc’s (NASDAQ: BIIB) investigational Alzheimer’s drug aducanumab — a drug for which the company halted studies at one point last year — could finally see the light of day.

Latest Ratings for BIIB
DateFirmActionFromTo Jul 2020Morgan StanleyU…

aducanumab, Analyst Color, Analyst Ratings, Barclays, Benzinga, BIIB, Biotech, Carter Gould, Credit Suisse, Downgrades, Evan Seigerman, Jay Olson, Oppenheimer, Price Target, Raymond James, Reiteration, Steven Seedhouse, Trading Ideas, US09062X1037

Some Biogen Analysts Unimpressed By Explanation For Aducanumab Filing Delay

Biogen Inc (NASDAQ: BIIB) shares shed close to 10% Wednesday following the revelation that the BLA filing for the company’s Alzheimer’s invest

Latest Ratings for BIIB
DateFirmActionFromTo Apr 2020SunTrust Robinson HumphreyMaintainsBuy Apr 2020Mor…